These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer. Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653 [TBL] [Abstract][Full Text] [Related]
27. Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor. Zhang Y Pharmacol Rev; 2023 Nov; 75(6):1218-1232. PubMed ID: 37339882 [TBL] [Abstract][Full Text] [Related]
29. EGFR inhibitors and autophagy in cancer treatment. Cui J; Hu YF; Feng XM; Tian T; Guo YH; Ma JW; Nan KJ; Zhang HY Tumour Biol; 2014 Dec; 35(12):11701-9. PubMed ID: 25293518 [TBL] [Abstract][Full Text] [Related]
30. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance. Wu M; Zhang P Cancer Lett; 2020 Jan; 469():207-216. PubMed ID: 31639425 [TBL] [Abstract][Full Text] [Related]
31. ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways. Fichter CD; Gudernatsch V; Przypadlo CM; Follo M; Schmidt G; Werner M; Lassmann S J Mol Med (Berl); 2014 Nov; 92(11):1209-23. PubMed ID: 25091467 [TBL] [Abstract][Full Text] [Related]
32. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Sabbah DA; Hajjo R; Sweidan K Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699 [TBL] [Abstract][Full Text] [Related]
33. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance. Chen Y; Lu A; Hu Z; Li J; Lu J Cancer Lett; 2024 Sep; 599():217146. PubMed ID: 39098760 [TBL] [Abstract][Full Text] [Related]
34. Targeting the EGFR signaling pathway in cancer therapy. Seshacharyulu P; Ponnusamy MP; Haridas D; Jain M; Ganti AK; Batra SK Expert Opin Ther Targets; 2012 Jan; 16(1):15-31. PubMed ID: 22239438 [TBL] [Abstract][Full Text] [Related]
35. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Oxnard GR; Arcila ME; Chmielecki J; Ladanyi M; Miller VA; Pao W Clin Cancer Res; 2011 Sep; 17(17):5530-7. PubMed ID: 21775534 [TBL] [Abstract][Full Text] [Related]
36. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. Zhao Y; Wang H; He C J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758 [TBL] [Abstract][Full Text] [Related]
37. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Ng YK; Lee JY; Supko KM; Khan A; Torres SM; Berwick M; Ho J; Kirkwood JM; Siegfried JM; Stabile LP Melanoma Res; 2014 Jun; 24(3):207-18. PubMed ID: 24709886 [TBL] [Abstract][Full Text] [Related]
38. Novel targeted radiosensitisers in cancer treatment. Zaidi SH; Huddart RA; Harrington KJ Curr Drug Discov Technol; 2009 Jun; 6(2):103-34. PubMed ID: 19519337 [TBL] [Abstract][Full Text] [Related]
39. Targeting HER3 to overcome EGFR TKI resistance in NSCLC. Chen Q; Jia G; Zhang X; Ma W Front Immunol; 2023; 14():1332057. PubMed ID: 38239350 [TBL] [Abstract][Full Text] [Related]
40. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Yamaguchi H; Chang SS; Hsu JL; Hung MC Oncogene; 2014 Feb; 33(9):1073-81. PubMed ID: 23542173 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]